



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31 DECEMBER 2018

Rs. Crore

Sr. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	478.29	422.91	262.68	1,263.04	713.44	1,000.96
II	Other Income	0.85	5.79	0.83	8.17	3.20	6.33
III	Total revenue (I+II)	479.14	428.70	263.51	1,271.21	716.64	1,007.29
IV	Expenses						
	Cost of materials consumed	291.87	261.25	157.87	763.39	443.14	617.01
	Changes in inventories of finished goods and work-in-progress	(14.26)	27.62	27.33	75.85	41.76	78.27
	Employee benefits expense	22.22	19.10	14.32	59.22	41.86	56.10
	Finance costs	12.85	13.90	15.58	42.59	49.33	64.35
	Depreciation and amortization expense	8.38	8.16	7.64	24.46	22.52	30.21
	Excise duty on sale of goods	-	-	-	-	17.66	17.66
	Other expenses	42.95	39.84	31.21	112.07	81.80	112.39
	Total Expenses	364.01	369.87	253.95	1,077.58	698.07	975.99
V	Profit before exceptional items and tax (III-IV)	115.13	58.83	9.56	193.63	18.57	31.30
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V-VI)	115.13	58.83	9.56	193.63	18.57	31.30
VIII	Tax Expense						
	(i) Current tax	24.80	12.67	2.14	41.71	4.16	6.72
	(ii) Deferred tax	8.09	7.76	(1.38)	16.87	(1.80)	(3.12)
	Total tax expense	32.89	20.43	0.76	58.58	2.36	3.60
IX	Profit for the period for continuing operations (VII-VIII)	82.24	38.40	8.80	135.05	16.21	27.70
X	Profit/(loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(loss) from discontinued operations (after tax)	-	-	-	-	-	-
XIII	Profit for the period	82.24	38.40	8.80	135.05	16.21	27.70
XIV	Other Comprehensive Income						
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(0.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	0.34
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period	82.24	38.40	8.80	135.05	16.21	27.05
XVI	Paid-up equity share capital (Face value Rs. 10/- per share)	56.21	56.21	56.21	56.21	56.21	56.21
XVII	Earning per equity share of Rs. 10/- each (for continuing and discontinued operations) (not annualised except for year ended 31.03.2018)						
	Basic	14.63	6.84	1.56	24.03	2.88	4.93
	Diluted	14.63	6.84	1.56	24.03	2.88	4.93
	Cash	17.56	9.67	2.68	31.38	6.57	9.75



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

Rs. Crore

Sr.No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	31.03.2018 (Audited)
1	Segment Revenue						
	(Net sale/income)						
	- Chemicals	217.88	196.33	130.14	571.20	348.76	489.28
	- Drugs	314.68	270.11	166.36	830.94	441.81	624.44
	- Unallocated	3.81	7.83	2.38	16.89	5.76	11.19
	Total	536.37	474.27	298.88	1,419.03	796.33	1,124.91
	Less : Inter segment revenue	57.23	45.57	35.37	147.82	97.35	135.28
	Net sales/income from operations	479.14	428.70	263.51	1,271.21	698.98	989.63
2	Segment Results						
	Profit before tax and interest from each segment)						
	- Chemicals	6.45	4.96	1.42	13.89	2.68	4.23
	- Drugs	119.91	66.07	23.33	217.49	63.64	88.96
	Total	126.36	71.03	24.75	231.38	66.32	93.19
	Less: Interest	12.85	13.90	15.58	42.59	49.33	64.35
	Add: Other un-allocable income net off un-allocable expenditure	1.62	1.70	0.39	4.84	1.58	2.46
	Total Profit before tax & Extraordinary items	115.13	58.83	9.56	193.63	18.57	31.30
3	Segment Assets						
	- Chemicals	312.24	287.90	291.35	312.24	291.35	309.83
	- Drugs	533.12	498.43	478.60	533.12	478.60	443.53
	- Unallocated	53.53	47.79	51.28	53.53	51.28	68.32
	Total Assets	898.89	834.12	821.23	898.89	821.23	821.68
4	Segment Liabilities						
	- Chemicals	247.81	224.60	271.76	247.81	271.76	254.21
	- Drugs	278.53	303.45	318.99	278.53	318.99	298.46
	- Unallocated	21.77	37.52	25.76	21.77	25.76	53.27
	Total Liabilities	548.11	565.57	616.51	548.11	616.51	605.94

NOTES:

- The above results have been reviewed by the Audit & Risk Management Committee and thereafter approved by the Board of Directors in their respective meetings held on 12 February 2019 and these results have been subjected to limited review by the Statutory Auditors.
- Excise duty realised is included in revenue from operations of periods upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and service tax (GST). Accordingly, the figure of revenue from operations for the nine months period ended 31 December 2018 is not comparable with the figures of nine months period ended 31 December 2017.
- Effective 1 April 2018, the company has adopted Ind AS 115 revenue from contracts with customers and its application did not have any material impact on the financial results of the company.
- The previous financial period figures have been regrouped/rearranged wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited



Vijay Garg
Managing Director
DIN: 06510248

Place: Ludhiana
Date: 12 February 2019

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

Limited Review Report


To
The Board of Directors
IOL Chemicals and Pharmaceuticals Ltd.
85, Industrial Area-A
Ludhiana

1. We have reviewed the unaudited Ind AS financial results of M/s IOL Chemicals and Pharmaceuticals Ltd. (the "Company") for the quarter ended December 31, 2018 and the year to date results for the period April 1, 2018 to December 31, 2018(the "Statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), read with SEBI Circular CIR/CFD/FAC/62/2016 dated July 5, 2016 ('the Circular').
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended, read with 'the Circular' and other accounting principles generally accepted in India is the responsibility of the management of the Company and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of 'the Regulation', read with 'the Circular' including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The comparative financial results of the Company for the quarter and nine months period ended December 31, 2017, included in this Statement were reviewed by the predecessor Auditor, who, vide their Report dated February 12, 2018 expressed an unmodified opinion on these financial results. Also, the Ind AS financial statements of the Company for the year ended March 31, 2018, were audited by predecessor auditor who expressed an unmodified opinion on those Ind AS financial statements on May 16, 2018. Our opinion is not modified in respect of this matter.

For Ashwani & Associates
Chartered Accountants


(Arvind Jain)
Partner
M. No. 097549



Place : Ludhiana
Dated : 12.02.2019